Abstract | BACKGROUND: METHODS: Exploratory posthoc analysis was performed on the 413 patients enrolled in Clazosentan to Overcome Neurological iSChemia and Infarction OccUrring after Subarachnoid hemorrhage (CONSCIOUS-1), a prospective randomized control trial of clazosentan for the prevention of vasospasm after aSAH. The association between potential clinical and radiographic covariates, and the length of stay (LOS) in a critical care unit after aSAH was determined using a Cox proportional hazards model. Covariates with a significance level of p < 0.20, on univariate analysis, were entered into a multivariate forward conditional analysis to identify independent predictors of prolonged LOS. RESULTS: The mean LOS was 12.6 ± 10.6 days. On multivariate analysis, age (hazard ratio [HR] 1.01, 95 % confidence interval [CI] 1.00-1.02; p = 0.032), a history of hypertension (HR 1.30, CI 1.01-1.67; p = 0.045), and a World Federation of Neurosurgical Societies Score of IV-V on admission (HR 1.38, CI 1.05-1.81; p = 0.02) were the clinical features associated with a greater critical care LOS following aSAH. Intracerebral hemorrhage (HR 1.50, CI 1.03-2.21; p = 0.004) and increasing intraventricular clot burden (HR 1.08, CI 1.03-1.14; p = 0.037) on admission computed tomography were the radiologic features associated with prolonged LOS. CONCLUSIONS: We have identified several early risk factors associated with a prolonged critical care stay following aSAH.
|
Authors | Christopher D Witiw, George M Ibrahim, Aria Fallah, R Loch Macdonald |
Journal | Neurocritical care
(Neurocrit Care)
Vol. 18
Issue 3
Pg. 291-7
(Jun 2013)
ISSN: 1556-0961 [Electronic] United States |
PMID | 23371849
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dioxanes
- Endothelin A Receptor Antagonists
- Pyridines
- Pyrimidines
- Sulfonamides
- Tetrazoles
- clazosentan
|
Topics |
- Adult
- Age Factors
- Aneurysm, Ruptured
(complications, epidemiology)
- Brain
(diagnostic imaging)
- Cerebral Ventricles
- Dioxanes
(therapeutic use)
- Endothelin A Receptor Antagonists
- Female
- Humans
- Hypertension
(complications)
- Intensive Care Units
(statistics & numerical data)
- Intracranial Aneurysm
(complications, epidemiology)
- Length of Stay
(statistics & numerical data)
- Male
- Middle Aged
- Multivariate Analysis
- Proportional Hazards Models
- Prospective Studies
- Pyridines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Risk Factors
- Severity of Illness Index
- Subarachnoid Hemorrhage
(diagnostic imaging, epidemiology, etiology)
- Sulfonamides
(therapeutic use)
- Tetrazoles
(therapeutic use)
- Tomography, X-Ray Computed
- Vasospasm, Intracranial
(etiology, prevention & control)
|